Jun 04, 2008 -
Pharmacopeia (NASDAQ: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced that it has identified a new lead compound for advancement in its alliance with
GlaxoSmithKline (NYSE: GSK), through its collaboration with the Center of Excellence for External Drug Discovery (CEEDD). This newly identified lead compound is the second from a program being evaluated as a potential treatment for respiratory disease.
As a result of this identification, Pharmacopeia received a $500,000 milestone payment from GSK...
Pharmacopeia's Press Release -
